Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor"
Deadline for manuscript submissions: closed (15 May 2019).
Interests: applied and experimental oncology; fibroblast growth factor receptor signaling; telomere maintenance mechanisms; alternative splicing; human and canine tumor cell models; novel therapeutic strategies; biomarkers
* h-index: 24
Interests: cellular and molecular tumor biology; in vitro models; colon adenomas and carcinomas; growth factor receptor signaling; therapy response, prognostic and predictive markers
* h-index: 31
Signaling by fibroblast growth factors (FGFs) and their receptors is crucial for embryonic development and in the adult organism. These protein family members of ligands and receptors are also dysregulated in the majority of malignant diseases. Important functions of FGFRs and related tyrosine receptor kinases in healthy and cancer cells have been deciphered and several mostly multi-target inhibitors are already in clinical trials or used as cancer drugs. However, the complex mechanisms underlying the impact of FGFR signaling on the cancer cells—their growth, survival and invasiveness—are still not completely understood. In addition, the ways in which FGFs interact with healthy cells in a paracrine manner driving angiogenesis and metastasis need to be further elucidated to define therapeutic targets and predictive markers for cancer therapy.
This Special Issue is calling for reviews and original papers covering translational research on FGFR signaling from basic science to clinical studies with strong emphasis on the improvement of knowledge for clinical application.
Dr. Klaus Holzmann
Dr. Brigitte Marian
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tyrosine-protein kinases
- cellular signaling mechanisms
- signaling crosstalk
- tumor microenvironment
- epithelial–mesenchymal transition (EMT)
- targeted therapy
- therapy response